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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive 
summary of evidence. 
 
COVID-19 Preparedness and Response 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
29.04.2020 Remdesivir in 
adults with severe 
COVID-19: a 
randomised, 
double-blind, 
placebo-
controlled, 
multicentre trial 
The Lancet | 
Article 
 First randomised trial of 
remdesivir suggests this 
antiviral drug was not 
associated with statistically 
significant clinical benefit in 
adult patients admitted to 
hospital for severe COVID-19 
beyond standard care: study of 
237 adults from 10 hospitals in 
Wuhan 
 Note that the trial was stopped 
early by the data safety 
monitoring board and did not 
reach the predetermined 
sample size due to the 
outbreak being brought under 
control in China  
 Absence of significance in an 
underpowered trial means 
findings are inconclusive 
 Time to clinical improvement 
and duration of invasive 
mechanical ventilation were 
shorter in people treated with 
remdesiver within 10 days of 
showing symptoms, compared 
with standard care  
2 
27.04.2020 Aerodynamics 
analysis of SARS-
CoV-2 in two 
Wuhan hospitals  
Nature | Article 
 Potential for transmission of 
SARS-CoV-2 via aerosol is 
poorly understood 
 This study measured viral RNA 
(note not infectivity of 
aerosolised virus) in aerosols 
in different areas of two Wuhan 
hospitals during the C19 
outbreak in February and 
March 2020 
 The concentration of SARS-
CoV-2 RNA in aerosols 
detected in isolation wards and 
ventilated patient rooms was 
very low and undetectable in 
the majority of public areas, but 
higher in the patients’ toilet 
areas and in public areas 
prone to crowding 
 Room ventilation, open space, 
sanitisation of protective 
apparel, and proper use and 
disinfection of toilet areas can 
effectively limit the 
concentration of SARS-CoV-2 
RNA in aerosols. 
  
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Description 
28.04.2020 COVI-PREG CHUV   International COVID-19 and 
Pregnancy   Registry 
28.04.2020 Accessibility Campaign – 
COVID-19 
International 
Disability 
Alliance 
  Call for PH information and 
communications around COVID-
19 to be fully accessible 
24.04.2020 Handwashing compendium 
for low resource settings: a 
living document (edition 1) 
IDS Sanitation 
Learning Hub 
  
 Ongoing WHO Country & Technical 
Guidance 
WHO   
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 Ongoing Inter-Agency Standing 
Committee (IASC) 
IASC   
Comments, Editorials, Correspondence, Blogs, News 
Publication 
date 
Title/URL Journal | Publication type 
29.04.2020 Remdesivir for COVID-19: challenges of 
underpowered studies 
The Lancet | Comment 
28.04.2020 Immunotherapies for COVID-19: lessons learned 
from sepsis 
The Lancet Respiratory 
Medicine | Comment 
28.04.2020 Limiting the spread of COVID-19 in Africa: one size 
mitigation strategies do not fit all countries 
The Lancet | 
Correspondence 
28.04.2020 Covid-19 - A reminder to reason NEJM | Perspective 
28.04.2020 The race for coronavirus vaccines: a graphical 
guide 
Nature | News Feature 
28.04.2020 Let Africa into the market for COVID-19 diagnostics Nature | World View 
27.04.2020 Whose coronavirus strategy worked best? 
Scientists hunt most effective policies 
Nature | News 
28.04.2020 Pick of the coronavirus papers: ‘Dry swabbing’ 
offers a workaround to test-chemical scarcity 
Nature | News 
28.04.2020 Learning to live with the new coronavirus: 
anticipation, articulation, adaptation and 
accountability 
Dr David Nabarro | C19 
Narrative 
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Tracking Dashboards 
Cases & 
deaths: Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
  Diagnostics   Treatments   Vaccines 
WHO sitreps WHO Africa Ghana   FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Arguments 
Indonesia   Serology-
based tests for 
COVID-19 
 US NIH 
registered clinical 
trials 
  Vaccine 
Centre 
LSHTM 
Johns Hopkins 
University 
European 
CDC 
Nigeria 
CDC 
   Solidarity trial   
WEF 
  Sierra 
Leone 
              COVID-19 
Therapeutics 
Accelerator 
 
Our World in 
Data 
  Singapore       
Global 5050   UK       
CEBM, 
University of 
Oxford 
  US       
Humanitarian 
Data 
Exchange 
          
Information is 
Beautiful 
          
LSHTM           
HealthMap 
(cases) 
          
5 
The Commons 
Project 
          
C19 Resource Hubs 
Global  Regional 
& 
Country 
Academic 
journals & 
Publishers 
Global Health 
Institutes/Centres 
Health 
Topics 
  Social 
Sciences 
WHO COVID-
19 pandemic  
Africa 
CDC 
The Lancet LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communication 
African 
Union 
NEJM LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Elsevier ICL MRC Centre 
for Global 
Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
  Disability 
and inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
BMJ ODI SLH: 
Handwashing 
in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
 
  Rings HSG 
Resyst 
Reach 
Wellcome 
UN African 
Academy 
of 
Sciences 
Cochrane 
resources 
Center for Global 
Development 
    Social 
Development 
Direct C19 
blog series 
UN Women   PLoS CMMID 
Repository 
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UNOCHA   Wiley 
Health 
Economics 
Norwegian 
Institute of Public 
Health 
    
UNHCR   Pre-prints 
medRxiv 
and 
bioRxiv 
CEBM, University 
of Oxford 
    
UNICEF      HEART     
UNESCO           
UN WFP           
GOARN           
World Bank           
COVID-19 
Narratives by 
David Nabarro 
          
Reliefweb           
Humanitarian 
OpenStreetMap 
Team 
          
Global 
Partnership for 
Sustainable 
Development 
Data 
          
WorldPop           
Flowminder           
COVID-END           
7 
Premise 
COVID-19 
Global Impact 
Study 
    
  
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
30.04.2020 
0730 BST 
COVID-19 open online 
briefing with Dr David 
Nabarro 
Event   4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods for 
detection, prevention, 
response and control 
Online learning 3 hours WHO 
Available 
now 
Responding to COVID-
19: Real-time training 
for the coronavirus 
disease outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
20 April 
2020 
COVID-19 Diagnostics 
and Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn 
University of 
Edinburgh & Royal 
College of Physicians 
of Edinburgh  
8 
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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